Immunovant, Inc. (IMVT)
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Symbol
- IMVT
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $7.69B
- 52 week range
- 14.86 - 45.42
Valuation
- Share price
- $34.54 (close of 2026-09-23)
- P/E (TTM)
- -13.27x
- Price to book
- 10.46x
- Price to free cash flow
- -18.56x
- Enterprise value
- $6.89B
- Book value per share
- $3.57
Price performance
| Period | Change |
|---|
| 1 day | -7.10% |
| 5 days | -5.76% |
| 1 month | -22.15% |
| 3 months | -8.19% |
| 6 months | +41.67% |
| Year to date | +35.88% |
| 1 year | +131.81% |
| 3 years | +69.40% |
| 5 years | +291.61% |
| All time | +247.14% |
Profitability and growth
- Return on equity
- -59.30%
- Return on assets
- -52.83%
- Net income growth
- -22.17%
- Free cash flow growth
- -8.15%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -5.39%
- Current ratio
- 7.27x
- Net debt to EBITDA
- 1.41x
Latest reported year
- Period end
- 2026-03-31
- Fiscal year
- 2026
- EBITDA
- $-504.98M
- Net income
- $-505.61M
- Earnings per share
- $-2.77
- Shares outstanding
- 182.42M
Income statement by year
| Period end | Net income | EPS |
|---|
| 2026-03-31 | $-505.61M | $-2.77 |
| 2025-03-31 | $-413.84M | $-2.73 |
| 2024-03-31 | $-259.34M | $-1.88 |
| 2023-03-31 | $-210.96M | $-1.71 |
| 2022-03-31 | $-156.73M | $-1.43 |
| 2021-03-31 | $-107.43M | $-1.22 |
| 2020-03-31 | $-66.39M | $-1.54 |
| 2019-03-31 | $-28.60M | $-1.29 |
Margins and returns by year
| Period end | Return on equity |
|---|
| 2026-03-31 | -59.30% |
| 2025-03-31 | -58.50% |
| 2024-03-31 | -41.98% |
| 2023-03-31 | -58.20% |
| 2022-03-31 | -33.36% |
| 2021-03-31 | -27.44% |
| 2020-03-31 | -70.57% |
| 2019-03-31 | -389.69% |
Cash and debt by year
| Period end | Cash |
|---|
| 2026-03-31 | $902.11M |
| 2025-03-31 | $713.97M |
| 2024-03-31 | $635.37M |
| 2023-03-31 | $376.53M |
| 2022-03-31 | $493.82M |
| 2021-03-31 | $400.15M |
| 2020-03-31 | $100.57M |
| 2019-03-31 | $6.99M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-03-31 | $-407.32M | $55.72M |
| 2025-03-31 | $-376.63M | $49.49M |
| 2024-03-31 | $-214.59M | $41.12M |
| 2023-03-31 | $-188.39M | $32.30M |
| 2022-03-31 | $-106.37M | $34.24M |
| 2021-03-31 | $-83.54M | $18.82M |
| 2020-03-31 | $-53.39M | $6.96M |
| 2019-03-31 | $-28.60M | $1.31M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | - |
| 2026-05-20 | - | - |
| 2026-02-06 | - | - |
| 2025-11-10 | - | - |
| 2025-08-11 | - | - |
| 2025-05-29 | - | - |
| 2025-02-06 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- immunovant.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades